FOMC minutes; Delta, PepsiCo to report; gold retreats - what’s moving markets
Director Ankit Mahadevia sold 6,572 shares of Spero Therapeutics Inc. (NASDAQ:SPRO) common stock on August 28, 2025, at a price of $1.97, totaling $12946. The transaction comes as SPRO shares trade at $2.05, having delivered a remarkable 167% return over the past six months. According to InvestingPro analysis, the stock is currently trading near its Fair Value, with a market capitalization of $115 million.
Following the transaction, Mahadevia directly owns 703,294 shares of Spero Therapeutics, Inc., which includes 65,817 shares held by the Mahadevia-Mehta Family Trust, of which Mahadevia is a trustee.
The sale was executed to cover tax withholding obligations related to the vesting of restricted stock units granted on August 26, 2021.
In other recent news, Spero Therapeutics reported impressive financial results for the second quarter of 2025, surpassing earnings and revenue expectations. The company achieved an earnings per share (EPS) of -$0.03, which was significantly better than the anticipated -$0.57, marking a 94.74% surprise. Additionally, Spero Therapeutics’ revenue reached $14.2 million, exceeding the forecasted $11 million. These results highlight the company’s strong performance in the recent quarter. No mergers or acquisitions were reported in the latest updates. Analyst upgrades or downgrades were not mentioned in the recent developments. Other company-specific news was not provided at this time. Investors will likely keep a close eye on Spero Therapeutics following these noteworthy earnings results.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.